News
Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...
Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...
Insider Monkey on MSN13h
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With NovoWe recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...
Explore more
10h
Zacks Investment Research on MSNHims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should KnowHims & Hers Health, Inc. (HIMS) ended the recent trading session at $50.46, demonstrating a -3.02% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered ...
On this news, the price of Hims' shares fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume. The first-filed case is Sookdeo v. Hims & Hers Health, ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
13don MSN
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results